GlassScriptPhysician profile
Misty Witten
NPI 1427449305
$1,727.04
in general payments reported to CMS, 2019-2025
23 companies · $534 in 2025
The $534 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $92.80 · 2023: $230 · 2024: $695 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328 · Consulting Fee: $116 · Education: $14.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.21 |
| Consulting Fee | $116.10 |
| Education | $14.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $362.20 | 2022-2025 | Fasenra |
| Glaxosmithkline, LLC. | $234.60 | 2021-2025 | Benlysta, Nucala |
| Genzyme Corporation | $167.88 | 2022-2024 | |
| Amgen INC. | $136.26 | 2021-2022 | |
| Adma Biomanufacturing LLC | $116.10 | 2024 | |
| Viiv Healthcare Company | $108.89 | 2023 | Apretude |
| Csl Behring | $67.24 | 2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $66.03 | 2024-2025 | Vpriv |
| Daiichi Sankyo INC. | $61.95 | 2021-2025 | Injectafer |
| Abbvie INC. | $57.07 | 2023-2025 | |
| Argenx US, INC. | $44.19 | 2024-2025 | Vyvgart Hytrulo |
| Biogen, INC. | $42.78 | 2024 | Leqembi |
| Regeneron Healthcare Solutions, INC. | $32.71 | 2025 | Evkeeza |
| Pharmacosmos Therapeutics INC. | $28.09 | 2025 | Monoferric |
| Horizon Therapeutics Plc | $26.98 | 2023 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $26.36 | 2025 | Fanapt |
| Chiesi USA, INC. | $25.82 | 2025 | Elfabrio |
| Janssen Pharmaceuticals, INC | $25.46 | 2024 | Spravato |
| Genentech USA, INC. | $24.13 | 2024 | Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $20.96 | 2025 | Rexulti |
| Lilly USA, LLC | $19.00 | 2023 | |
| Eisai INC. | $16.33 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $16.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Witten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.